MeiraGTx Holdings plc

NASDAQ•MGTX

執行長: Dr. Alexandria Forbes Ph.D.

板塊: Healthcare

行業: Biotechnology

上市日期: 2018-06-08

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

聯絡資訊

450 East 29th Street, 14th Floor, New York, NY, 10016, United States

646-860-7985

meiragtx.com

市值

$919.53M

本益比 (TTM)

-8.0

19.2

股息率

52周最高

$11.59

52周最低

$4.55

52周範圍

96%

排名67Top 97.6%

1.4

F-Score

改良版 Piotroski 分析

基於 9 年期基本面

疲弱 • 1.4 / 9 分

評分區間 (0-9)

8-9: 價值優異

6-7: 基本面強勁

4-5: 整體穩健

0-3: 表現疲弱

資料區間: 2017-2025

財務儀表板

Q4 2025 數據

營業收入

$75.36M+0.00%

近4季度走勢

每股收益

$0.19+0.00%

近4季度走勢

自由現金流

$39.86M+0.00%

近4季度走勢

2025 Q3 財報亮點

核心亮點

Hologen Strategic Collaboration Closed Received $28.0M deposit from Hologen; joint venture established for AAV-GAD Parkinson's program development.

Lilly Ophthalmology Deal Signed Secured exclusive worldwide rights for AAV-AIPL1; eligible for $75.0M upfront payment plus $400.0M milestones.

Service Revenue Significantly Decreased Nine-month service revenue fell $5.9M to $6.0M USD as PPQ services under Asset Purchase Agreement substantially completed.

RMAT Designations Secured Received FDA RMAT designation for AAV-hAQP1 (xerostomia) and AAV-GAD (Parkinson's), potentially accelerating review timelines.

關注風險

Persistent Operating Losses Incurred Accumulated deficit reached $831.3M USD as of September 30, 2025; expects substantial losses for foreseeable future.

Future Capital Requirements High Requires substantial additional financing for development; failure to raise capital risks delaying or eliminating key research and development programs.

Gene Therapy Regulatory Uncertainty Novel gene therapy platform faces uncertain regulatory landscape; predicting development time and cost remains difficult.

Manufacturing Capacity Constraints Reliance on third-party plasmid suppliers and internal facilities carries risk of delays or inability to meet regulatory requirements or commercial scale.

未來展望

Advance AAV-GAD Phase 3 Study Engaging global sites to initiate Phase 3 study for AAV-GAD Parkinson's treatment in the coming months following RMAT designation.

AAV-hAQP1 Pivotal Data Expected Phase 2 AQUAx2 study enrolling final cohorts; potential pivotal data readout supporting BLA filing targeted for early 2027.

Expand Riboswitch Platform Into Clinic Progressing first riboswitch program (human leptin) into clinic; demonstrated dose-response efficacy in mouse models over one year.

Cash Runway Extended to 2027 Estimated cash sufficient to fund operations into second half of 2027, supported by Lilly and Hologen funding milestones.

同行對比

營業收入 (TTM)

IOVA

$263.50M

+60.6%

ARVN

$262.60M

-0.3%

RGNX

$170.44M

+104.5%

毛利率 (最新季度)

IOVA

215.9%

+65.9pp

DNA

124.4%

-21.7pp

ATXS

100.0%

+0.0pp

關鍵指標

股票代碼	市值	本益比 (TTM)	股東權益報酬率 (TTM)	負債率
ERAS	$5.55B	-40.6	-34.5%	11.9%
KOD	$2.39B	-10.4	-255.4%	16.8%
NRIX	$1.41B	-6.1	-64.2%	9.2%

長期趨勢

近4季度

營業收入

淨利

營運現金流

4季度營業收入複合增長率

239.5%

高速增長

4季度淨利複合增長率

N/M

盈利狀態轉變

現金流穩定性

25%

現金流需要關注

深度研究

下次財報:2026年5月7日

每股收益:-$0.57

營業收入:$3.80M

財務數據

電話會議

財務報告

新聞

損益表

資產負債表

現金流量表

財務比率

變化率

損益表	過去12個月

無資料